LMW Heparin Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

Low molecular weight heparin is basically derived from unfractionated heparin with an average molecular weight containing less than 8,000 Da. Low molecular weight heparins are extracted mainly by enzymatic or chemical depolymerization from unfractionated heparin. Low molecular weight heparin contains fewer side effects as compared to unfractionated heparins, which further involve lesser risk of heparin-induced osteopenia along with heparin-induced thrombocytopenia (HIT). Currently, low molecular weight heparin has the standard of care drugs and is widely utilized for the treatment and prophylaxis of arterial as well as venous thrombosis. Dose consideration for low molecular weight heparin depends on a patient's weight.

MARKET DYNAMICS

The LMW heparin market has witnessed a significant growth owing to factors such as wider application in the treatment of venous thromboembolism, complications of pregnancy, cardioversion of atrial fibrillation/flutter, and others. Proven health benefits of low molecular weight heparin over the unfractionated heparin are boosting the demand for low molecular weight heparin across the globe, which in turn is fuelling the growth of this market. The rise in demand for low molecular weight heparin is anticipated to grow exponentially in the near future due to increasing usage in surgeries along with the treatment of coagulation disorders. However, lack of its ability to reverse mainly the effect of overdose resulting in the development of HIT as well as other bleeding disorders restrains the growth of the low molecular weight heparin market. Nevertheless, with the steady growth in the healthcare industry and biomedical sector, there are opportunities for the market players to invest in this market.

MARKET SCOPE

The "Global LMW Heparin Market Analysis to 2031” is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the LMW heparin market with detailed market segmentation by product type, application, and geography. The global LMW heparin market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading LMW heparin market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global LMW heparin market is segmented on the basis of product type, and application. On the basis of product type, the LMW heparin market is segmented into enoxaparin, dalteparin, tinzaparin, and fraxiparine. The LMW heparin market on the basis of the application is classified into treatment of venous thromboembolism, complications of pregnancy, cardioversion of atrial fibrillation/flutter, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global LMW heparin market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America. The LMW heparin market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the LMW heparin market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the LMW heparin market in these regions.

MARKET PLAYERS

The reports cover various key developments in the global LMW heparin market. Various companies are focusing growth strategies such as product launches, product approvals and others such as patents and events. Some of the growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from LMW heparin market are anticipated to lucrative growth opportunities in the future with the rising demand for LMW heparin in the global market. Below mentioned is the list of few companies engaged in the LMW heparin market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the LMW heparin market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

•   Aspen
  
•   Changzhou Qianhong Bio-pharma
  
•   CSBIO
  
•   Dongying Tiandong Pharmaceutical
  
•   Opocrin
  
•   Pfizer
  
•   Sanofi-aventis
  
•   Techdow
  
•   Yantai Dongcheng Pharmaceutical Group
  
•   Others
  

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

LMW Heparin Report Scope